Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis

Trial Profile

Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top